SELLAS Life Sciences Group, Inc. SLS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about SELLAS Life Sciences Group, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is SELLAS Life Sciences Group, Inc.'s additional paid-in capital?
- SELLAS Life Sciences Group, Inc. (SLS) reported additional paid-in capital of $390.79M in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s additional paid-in capital changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s additional paid-in capital increased by 38.7% year-over-year, from $281.69M to $390.79M.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s additional paid-in capital has grown at a 18.8% compound annual growth rate (CAGR), from $145.86M to $345.84M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.